Ocular Therapeutix (OCUL) Releases Earnings Results, Misses Estimates By $0.02 EPS

Ocular Therapeutix (NASDAQ:OCUL) posted its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.02), Morningstar.com reports. The firm had revenue of $0.50 million for the quarter, compared to analysts’ expectations of $0.45 million. Ocular Therapeutix had a negative return on equity of 143.32% and a negative net margin of 2,814.72%.

NASDAQ OCUL traded up $0.27 on Thursday, hitting $5.68. 23,665 shares of the stock were exchanged, compared to its average volume of 387,048. The company has a quick ratio of 4.91, a current ratio of 4.92 and a debt-to-equity ratio of 0.21. The firm has a market capitalization of $202.22 million, a price-to-earnings ratio of -2.29 and a beta of 1.55. Ocular Therapeutix has a 52-week low of $3.30 and a 52-week high of $8.28.

Several research analysts have commented on OCUL shares. Piper Jaffray Companies started coverage on shares of Ocular Therapeutix in a research note on Thursday, September 6th. They set an “overweight” rating for the company. Zacks Investment Research lowered shares of Ocular Therapeutix from a “buy” rating to a “hold” rating in a research note on Wednesday, August 15th. Cantor Fitzgerald set a $22.00 price objective on shares of Ocular Therapeutix and gave the stock a “buy” rating in a research note on Wednesday, October 3rd. BidaskClub lowered shares of Ocular Therapeutix from a “hold” rating to a “sell” rating in a research note on Tuesday, October 9th. Finally, ValuEngine lowered shares of Ocular Therapeutix from a “hold” rating to a “sell” rating in a research note on Friday, September 14th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $12.00.

In other Ocular Therapeutix news, CEO Antony C. Mattessich bought 20,000 shares of the firm’s stock in a transaction dated Monday, August 20th. The stock was acquired at an average cost of $5.95 per share, for a total transaction of $119,000.00. Following the completion of the transaction, the chief executive officer now owns 57,900 shares in the company, valued at $344,505. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, insider Antony C. Mattessich bought 16,900 shares of the firm’s stock in a transaction dated Friday, August 10th. The shares were acquired at an average price of $6.23 per share, with a total value of $105,287.00. Following the completion of the transaction, the insider now owns 37,900 shares of the company’s stock, valued at approximately $236,117. The disclosure for this purchase can be found here. Insiders have acquired 49,400 shares of company stock valued at $302,912 over the last ninety days. 15.90% of the stock is owned by insiders.

Large investors have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp lifted its position in shares of Ocular Therapeutix by 13.6% during the second quarter. Bank of New York Mellon Corp now owns 94,294 shares of the biopharmaceutical company’s stock worth $636,000 after purchasing an additional 11,276 shares during the last quarter. Schwab Charles Investment Management Inc. lifted its position in shares of Ocular Therapeutix by 35.4% during the second quarter. Schwab Charles Investment Management Inc. now owns 72,559 shares of the biopharmaceutical company’s stock worth $490,000 after purchasing an additional 18,989 shares during the last quarter. The Manufacturers Life Insurance Company lifted its position in shares of Ocular Therapeutix by 328.4% during the first quarter. The Manufacturers Life Insurance Company now owns 24,123 shares of the biopharmaceutical company’s stock worth $157,000 after purchasing an additional 18,492 shares during the last quarter. Millennium Management LLC lifted its position in shares of Ocular Therapeutix by 91.0% during the first quarter. Millennium Management LLC now owns 42,369 shares of the biopharmaceutical company’s stock worth $276,000 after purchasing an additional 20,192 shares during the last quarter. Finally, Hikari Power Ltd lifted its position in shares of Ocular Therapeutix by 50.0% during the third quarter. Hikari Power Ltd now owns 120,001 shares of the biopharmaceutical company’s stock worth $826,000 after purchasing an additional 39,990 shares during the last quarter. Institutional investors and hedge funds own 56.96% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Ocular Therapeutix (OCUL) Releases Earnings Results, Misses Estimates By $0.02 EPS” was originally reported by WKRB News and is owned by of WKRB News. If you are reading this story on another website, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this story can be read at https://www.wkrb13.com/2018/11/08/ocular-therapeutix-ocul-releases-earnings-results-misses-estimates-by-0-02-eps.html.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. Its lead product candidates include DEXTENZA (dexamethasone insert) for the treatment of post-surgical ocular pain and inflammation, allergic conjunctivitis, and dry eye diseases; and OTX-TP (travoprost insert) for the reduction of intraocular pressure (IOP) in patients with glaucoma and ocular hypertension.

Featured Story: Can individual investors take part in an IPO?

Earnings History for Ocular Therapeutix (NASDAQ:OCUL)

Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply